Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Ophthalmology

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 31 articles:
HTML format



Single Articles


    September 2025
  1. KIRTANE AJ, Stone GW
    Orbital atherectomy for stent implantation: the ECLIPSE trial - Authors' reply.
    Lancet. 2025;406:1221-1222.
    PubMed    


  2. KHIALANI B, Frazzetto M, Touma G, Cortese B, et al
    Orbital atherectomy for stent implantation: the ECLIPSE trial.
    Lancet. 2025;406:1220.
    PubMed    


  3. PROTTY MB, Hussain H, Hailan A, Choudhury A, et al
    Orbital atherectomy for stent implantation: the ECLIPSE trial.
    Lancet. 2025;406:1220-1221.
    PubMed    


    May 2025
  4. HABTAMU E, Harding-Esch EM, Greenland K, Wamyil-Mshelia T, et al
    Trachoma.
    Lancet. 2025;405:1865-1878.
    PubMed     Abstract available


    March 2025
  5. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    PubMed     Abstract available


  6. COUGHLAN JJ, Byrne RA
    Orbital atherectomy for severely calcified coronary artery lesions.
    Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
    PubMed    


    February 2025
  7. MICHAELIDES M, Laich Y, Wong SC, Oluonye N, et al
    Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.
    Lancet. 2025;405:648-657.
    PubMed     Abstract available


    January 2025
  8. ACHARYA NR, Ramanan AV, Coyne AB, Dudum KL, et al
    Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
    Lancet. 2025;405:303-313.
    PubMed     Abstract available


  9. FOELL D, Heiligenhaus A
    Uveitis in juvenile idiopathic arthritis: when to stop adalimumab?
    Lancet. 2025;405:274-276.
    PubMed    


    November 2024
  10. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
    Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
    Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
    PubMed     Abstract available


  11. HIRAMI Y, Mandai M
    Opening the door to widespread iPSC-derived regenerative therapy for corneal epithelial opacity.
    Lancet. 2024 Nov 7:S0140-6736(24)01965-2. doi: 10.1016/S0140-6736(24)01965.
    PubMed    


    September 2024
  12. YANG P, Pardon LP, Ho AC, Lauer AK, et al
    Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.
    Lancet. 2024;404:962-970.
    PubMed     Abstract available


  13. MACLAREN RE
    Gene therapy in the early stages of retinal degeneration.
    Lancet. 2024;404:911-913.
    PubMed    


    August 2024
  14. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    PubMed     Abstract available


  15. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    PubMed    


  16. FISHER BA, Mariette X, Papas A, Grader-Beck T, et al
    Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Lancet. 2024;404:540-553.
    PubMed     Abstract available


  17. COLAFRANCESCO S, Priori R
    Sjogren's disease: a new era for clinical trials?
    Lancet. 2024;404:498-499.
    PubMed    


    July 2024
  18. PATEL JN, Miller NR
    Non-arteritic anterior ischaemic optic neuropathy causes sudden-onset painless loss of vision.
    Lancet. 2024;404:67.
    PubMed    


    June 2024
  19. YING GS, VanderBeek BL
    Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
    Lancet. 2024 Jun 11:S0140-6736(24)00915-2. doi: 10.1016/S0140-6736(24)00915.
    PubMed    


  20. JACKSON TL, Desai R, Wafa HA, Wang Y, et al
    Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
    Lancet. 2024 Jun 11:S0140-6736(24)00687-1. doi: 10.1016/S0140-6736(24)00687.
    PubMed     Abstract available


    May 2024
  21. PROUDLOCK FA, Hisaund M, Maconachie G, Papageorgiou E, et al
    Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.
    Lancet. 2024;403:1766-1778.
    PubMed     Abstract available


  22. ZHOU S, Zhou J
    New advances in amblyopia therapy: early patching is more effective than extended optical treatment.
    Lancet. 2024;403:1725-1727.
    PubMed    


    April 2024
  23. WILENIUS M, Jernman J, Hietaharju A, Salonen T, et al
    Swollen eyelids caused by polyvinylpyrrolidone histiocytosis with intravenous methylphenidate.
    Lancet. 2024;403:1574-1575.
    PubMed    


    March 2024
  24. CAMPOCHIARO PA, Avery R, Brown DM, Heier JS, et al
    Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
    Lancet. 2024 Mar 27:S0140-6736(24)00310-6. doi: 10.1016/S0140-6736(24)00310.
    PubMed     Abstract available


  25. RAKOCZY EP
    The promise of long-term treatment for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 27:S0140-6736(24)00428-8. doi: 10.1016/S0140-6736(24)00428.
    PubMed    


  26. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available


  27. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    PubMed     Abstract available


  28. LANZETTA P, Korobelnik JF, Heier JS, Leal S, et al
    Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
    Lancet. 2024 Mar 7:S0140-6736(24)00063-1. doi: 10.1016/S0140-6736(24)00063.
    PubMed     Abstract available


  29. CHEW EY
    Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 7:S0140-6736(24)00229-0. doi: 10.1016/S0140-6736(24)00229.
    PubMed    


  30. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    PubMed    


    October 2023
  31. KHANANI AM, Patel SS, Staurenghi G, Tadayoni R, et al
    Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
    Lancet. 2023;402:1449-1458.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ophthalmology is free of charge.